NASDAQ:CTIC - CTI BioPharma Stock Price, Price Target & More

$3.90 +0.03 (+0.78 %)

(As of 04/25/2018 04:00 PM ET)

Previous Close$3.90

Today's Range$3.88 - $3.94

52-Week Range$2.45 - $4.31

Volume103,146 shs

Average Volume379,369 shs

Market Capitalization$226.13 million

P/E Ratio-3.15

Dividend YieldN/A

Beta0.14

About CTI BioPharma (NASDAQ:CTIC)

CTI BioPharma Corp., a biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel targeted therapies for blood-related cancers in the United States and internationally. It develops PIXUVRI, a novel aza-anthracenedione for the treatment of adult patients with multiply relapsed or refractory aggressive B-cell non-Hodgkin lymphoma; and pacritinib, an investigational oral kinase inhibitor with specificity for JAK2, FLT3, IRAK1, and CSF1R, which is in Phase III clinical trials for the treatment of adult patients with myelofibrosis. The company's product candidate in pipeline includes tosedostat, a novel oral, once-daily aminopeptidase inhibitor for patients with acute myeloid leukemia. It has license and collaboration agreement with Les Laboratoires Servier and Institut de Recherches Internationales Servier; Teva Pharmaceutical Industries Ltd; University of Vermont; S*BIO Pte Ltd; and Vernalis (R&D) Limited. The company was formerly known as Cell Therapeutics, Inc. and changed its name to CTI BioPharma Corp. in May 2014. CTI BioPharma Corp. was founded in 1991 and is headquartered in Seattle, Washington.

Receive CTIC News and Ratings via Email

Sign-up to receive the latest news and ratings for CTIC and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Pharmaceutical preparations

Sub-IndustryN/A

SectorMedical

SymbolNASDAQ:CTIC

CUSIPN/A

Webwww.ctibiopharma.com

Phone206-282-7100

Debt

Debt-to-Equity Ratio0.90%

Current Ratio2.44%

Quick Ratio2.41%

Price-To-Earnings

Trailing P/E Ratio-3.15

Forward P/E Ratio-4.33

P/E GrowthN/A

Sales & Book Value

Annual Sales$25.15 million

Price / Sales8.99

Cash FlowN/A

Price / CashN/A

Book Value$0.35 per share

Price / Book11.14

Profitability

EPS (Most Recent Fiscal Year)($1.24)

Net Income$-40,670,000.00

Net Margins-161.74%

Return on Equity-233.13%

Return on Assets-64.71%

Miscellaneous

Employees57

Outstanding Shares57,980,000

How to Become a New Pot Stock Millionaire

CTI BioPharma (NASDAQ:CTIC) Frequently Asked Questions

What is CTI BioPharma's stock symbol?

CTI BioPharma trades on the NASDAQ under the ticker symbol "CTIC."

When did CTI BioPharma's stock split? How did CTI BioPharma's stock split work?

CTI BioPharma's stock reverse split before market open on Tuesday, January 3rd 2017. The 1-10 reverse split was announced on Friday, December 9th 2016. The number of shares owned by shareholders was adjusted after the closing bell on Friday, December 30th 2016. An investor that had 100 shares of CTI BioPharma stock prior to the reverse split would have 10 shares after the split.

How were CTI BioPharma's earnings last quarter?

CTI BioPharma (NASDAQ:CTIC) released its quarterly earnings results on Wednesday, March, 7th. The biopharmaceutical company reported ($0.33) EPS for the quarter, missing the consensus estimate of ($0.29) by $0.04. The biopharmaceutical company earned $0.46 million during the quarter, compared to analyst estimates of $1 million. CTI BioPharma had a negative return on equity of 233.13% and a negative net margin of 161.74%. During the same period in the previous year, the business posted ($0.70) earnings per share. View CTI BioPharma's Earnings History.

When is CTI BioPharma's next earnings date?

CTI BioPharma is scheduled to release their next quarterly earnings announcement on Wednesday, May, 2nd 2018. View Earnings Estimates for CTI BioPharma.

What price target have analysts set for CTIC?

5 equities research analysts have issued 1-year target prices for CTI BioPharma's shares. Their forecasts range from $5.00 to $10.00. On average, they anticipate CTI BioPharma's stock price to reach $7.10 in the next twelve months. View Analyst Ratings for CTI BioPharma.

What are Wall Street analysts saying about CTI BioPharma stock?

Here are some recent quotes from research analysts about CTI BioPharma stock:

1. According to Zacks Investment Research, "CTI BioPharma Corp. is a biopharmaceutical company. It is focused on the acquisition, development and commercialization of therapies covering a spectrum of blood-related cancers. The company is heavily focused on marketing its approved therapy Pixuvri in Europe, and on continuing the development of its late-stage development pipeline, including pacritinib. CTI BioPharma Corp., formerly known as Cell Therapeutics, Inc., is headquartered in Seattle, Washington. " (4/25/2018)
2. Cann analysts commented, "CTI BioPharma released Q4 2017 results today with lower-than-expected sales and slightly higher-than-estimated SG&A. Total revenue of $462,000 was lower than our estimated $1.7 million. All revenue was from License and Contract Revenue. Total operating expenses of $14.2 million were 6.3% higher than our estimated $13.3 million due to higher-than-estimated SG&A expense. CTI BioPharma lost $0.33 per share compared to our estimated loss per share of $0.28. Our 2018–2024 outlook is basically unchanged for CTI BioPharma. Programs are advancing, with data expected in H1 2018." (3/7/2018)

Who are some of CTI BioPharma's key competitors?

Some companies that are related to CTI BioPharma include Amphastar Pharmaceuticals (AMPH), Assembly Biosciences (ASMB), Inflarx (IFRX), Lexicon Pharmaceuticals (LXRX), Amarin (AMRN), Mirati Therapeutics (MRTX), Eagle Pharmaceuticals (EGRX), Collegium Pharmaceutical (COLL), ARMO BioSciences (ARMO), Urogen Pharma (URGN), Vectura Group (VEGPF), OptiNose (OPTN), Deciphera Pharmaceuticals (DCPH), Adamas Pharmaceuticals (ADMS) and Vanda Pharmaceuticals (VNDA).

Who are CTI BioPharma's key executives?

CTI BioPharma's management team includes the folowing people:

Dr. Jack W. Singer, Co-Founder, Exec. VP, Chief Scientific Officer, Interim CMO & Global Head-Translational Medicine (Age 75)
Mr. Bruce J. Seeley, COO, Exec. VP & Sec. (Age 54)
Dr. Adam R. Craig, Pres, CEO & Director (Age 52)
Mr. David H. Kirske, Exec. VP & CFO (Age 64)
Mr. Ed Bell, Sr. Director of Investor Relations

Has CTI BioPharma been receiving favorable news coverage?

Press coverage about CTIC stock has been trending somewhat positive this week, according to Accern. Accern identifies positive and negative media coverage by analyzing more than 20 million news and blog sources. Accern ranks coverage of publicly-traded companies on a scale of negative one to one, with scores closest to one being the most favorable. CTI BioPharma earned a media sentiment score of 0.12 on Accern's scale. They also gave media headlines about the biopharmaceutical company an impact score of 45.29 out of 100, indicating that recent media coverage is somewhat unlikely to have an effect on the company's share price in the immediate future.

Who are CTI BioPharma's major shareholders?

CTI BioPharma's stock is owned by a number of of institutional and retail investors. Top institutional shareholders include GROWTH EQUITY OPPORTUNITIES V, LLC (6.00%). Company insiders that own CTI BioPharma stock include Bvf Partners L P/Il, James A Bianco, Richard L Love and Value Fund L P Biotechnology. View Institutional Ownership Trends for CTI BioPharma.

How do I buy shares of CTI BioPharma?

Shares of CTIC can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is CTI BioPharma's stock price today?

One share of CTIC stock can currently be purchased for approximately $3.90.

How big of a company is CTI BioPharma?

CTI BioPharma has a market capitalization of $226.13 million and generates $25.15 million in revenue each year. The biopharmaceutical company earns $-40,670,000.00 in net income (profit) each year or ($1.24) on an earnings per share basis. CTI BioPharma employs 57 workers across the globe.

How can I contact CTI BioPharma?

CTI BioPharma's mailing address is 3101 WESTERN AVENUE SUITE 800, SEATTLE WA, 98121. The biopharmaceutical company can be reached via phone at 206-282-7100 or via email at [email protected]

MarketBeat Community Rating for CTI BioPharma (CTIC)

Community Ranking:		2.4 out of 5 ( )
Outperform Votes:		152 (Vote Outperform)
Underperform Votes:		168 (Vote Underperform)
Total Votes:		320

MarketBeat's community ratings are surveys of what our community members think about CTI BioPharma and other stocks. Vote "Outperform" if you believe CTIC will outperform the S&P 500 over the long term. Vote "Underperform" if you believe CTIC will underperform the S&P 500 over the long term. You may vote once every thirty days.

CTI BioPharma (NASDAQ:CTIC) Price Target and Consensus Rating

(How are Consensus Ratings Calculated?)

5 Wall Street analysts have issued ratings and price targets for CTI BioPharma in the last 12 months. Their average twelve-month price target is $7.10, suggesting that the stock has a possible upside of 82.05%. The high price target for CTIC is $10.00 and the low price target for CTIC is $5.00. There are currently 5 buy ratings for the stock, resulting in a consensus rating of "Buy."

	Today	30 Days Ago	90 Days Ago	180 Days Ago
Consensus Rating:	Buy	Buy	Buy	Buy
Consensus Rating Score:	3.00	3.00	3.00	3.00
Ratings Breakdown:	0 Sell Rating(s) 0 Hold Rating(s) 5 Buy Rating(s) 0 Strong Buy Rating(s)	0 Sell Rating(s) 0 Hold Rating(s) 5 Buy Rating(s) 0 Strong Buy Rating(s)	0 Sell Rating(s) 0 Hold Rating(s) 1 Buy Rating(s) 0 Strong Buy Rating(s)	0 Sell Rating(s) 0 Hold Rating(s) 1 Buy Rating(s) 0 Strong Buy Rating(s)
Consensus Price Target:	$7.10	$7.10	$7.50	$7.50
Price Target Upside:	82.05% upside	83.94% upside	131.48% upside	131.48% upside

CTI BioPharma (NASDAQ:CTIC) Consensus Price Target History

Price Target History for CTI BioPharma (NASDAQ:CTIC)

CTI BioPharma (NASDAQ:CTIC) Analyst Ratings History

Show:

Date	Brokerage	Action	Rating	Price Target	Impact on Share Price
3/26/2018	Needham & Company LLC	Initiated Coverage	Buy -> Buy	$10.00	High
3/7/2018	Cann	Reiterated Rating	Buy	$5.00	Low
3/7/2018	JMP Securities	Initiated Coverage	Mkt Outperform -> Outperform	$8.00	Low
2/23/2018	Oppenheimer	Initiated Coverage	Outperform	$5.00 -> $5.00	High
9/12/2017	Jefferies Group	Initiated Coverage	Buy -> Buy	$7.50	High
8/29/2016	Piper Jaffray	Reiterated Rating	Neutral	$7.50	N/A

(Data available from 4/25/2016 forward)

CTI BioPharma (NASDAQ:CTIC) Earnings History and Estimates Chart

Earnings by Quarter for CTI BioPharma (NASDAQ:CTIC)

CTI BioPharma (NASDAQ:CTIC) Earnings Estimates

2018 EPS Consensus Estimate: ($1.05)

Quarter	Number of Estimates	Low Estimate	High Estimate	Average Estimate
Q1 2018	1	($0.07)	($0.07)	($0.07)
Q2 2018	1	($0.26)	($0.26)	($0.26)
Q3 2018	1	($0.30)	($0.30)	($0.30)
Q4 2018	1	($0.42)	($0.42)	($0.42)

CTI BioPharma (NASDAQ CTIC) Earnings History by Quarter

Date	Quarter	Consensus Estimate	Actual EPS	Revenue Estimate	Actual Revenue	Release Link	Conference Call
5/2/2018
3/7/2018	Q4 2017	($0.29)	($0.33)	$1.00 million	$0.46 million	View	Listen
11/6/2017	Q3 2017	($0.32)	($0.28)	$0.30 million	$1.71 million	View	N/A
8/3/2017	Q2 2017	($0.60)	$0.03		$22.23 million	View	Listen
5/3/2017	Q1 2017	($0.70)	($0.71)		$0.75 million	View	Listen
3/2/2017	Q4 2016	($0.70)	($0.23)		$9.14 million	View	Listen
11/8/2016	Q3 2016	($0.70)	($1.00)		$4.43 million	View	N/A
8/4/2016	Q2	($0.10)	($0.07)		$7.36 million	View	N/A
5/10/2016	Q1	($0.04)	$0.01		$36.48 million	View	N/A
2/16/2016	Q4	($0.18)	($0.13)		$11.32 million	View	N/A
11/5/2015	Q315	($0.12)	($0.19)	$18.89 million	$1.00 million	View	Listen
8/6/2015	Q215	($0.10)	($0.19)	$12.77 million	$1.10 million	View	Listen
5/6/2015	Q115	($0.14)	($0.16)	$9.84 million	$2.73 million	View	Listen
3/12/2015	Q414	($0.18)	($0.27)	$2.48 million	$17.80 million	View	Listen
10/29/2014	Q3	$0.03	$0.03	$21.52 million	$39.53 million	View	Listen
8/4/2014	Q2	($0.12)	($0.19)	$11.79 million	$1.34 million	View	Listen
4/29/2014	Q114	($0.20)	($0.20)	$1.10 million	$1.40 million	View	N/A
3/4/2014	Q4	($0.16)	$0.08	$1.26 million	$32.90 million	View	Listen
10/30/2013	Q3 2013	($1.70)	($2.00)	$2.00 million	$0.36 million	View	N/A
7/31/2013	Q2 2013	($1.70)	($1.70)	$1.50 million	$0.31 million	View	N/A
5/2/2013	Q1 2013	($4.40)	($1.80)		$1.13 million	View	N/A
2/28/2013	Q4 2012	($0.20)	($0.20)	$1.00 million		View	Listen
11/1/2012	Q312		($0.38)			View	N/A
8/1/2012	Q2 2012		($7.15)			View	N/A
4/20/2012	Q1 2012	($5.00)	($4.30)			View	N/A
3/7/2012	Q4 2011	($4.00)	($7.40)			View	N/A
10/25/2011	Q3 2011	($5.50)	($8.00)			View	N/A
7/28/2011	Q2 2011	($6.00)	($6.80)			View	N/A
4/27/2011	Q1 2011	($6.00)	($17.40)			View	N/A
2/16/2011	Q4 2010	($6.00)	($12.00)			View	N/A
10/28/2010	Q3 2010	($18.00)	($6.60)			View	N/A
8/5/2010	Q2 2010	($6.00)	($23.10)			View	N/A
4/28/2010	Q1 2010		($22.20)			View	N/A
2/11/2010	Q4 2009	($9.00)	($14.40)			View	N/A
11/5/2009	Q3 2009		($27.89)			View	N/A
8/6/2009	Q2 2009	($15.00)	($15.30)			View	N/A
5/7/2009	Q1 2009	($80.98)	($26.99)			View	N/A
3/16/2009	Q4 2008	($287.94)	($162.57)			View	N/A
11/7/2008	Q3 2008	($1,019.80)	($850.03)			View	N/A
8/18/2008	Q2 2008	($1,049.79)	($1,406.72)			View	N/A
5/8/2008	Q1 2008	($1,409.72)	($2,303.54)			View	N/A
3/13/2008	Q4 2007	($1,649.67)	($2,231.55)			View	N/A

(Earnings results data provided by Zacks Investment Research)

CTI BioPharma (NASDAQ:CTIC) Dividend History by Quarter

Announced	Period	Amount	Yield	Ex-Dividend Date	Record Date	Payable Date

(Data available from 1/1/2013 forward)

CTI BioPharma (NASDAQ CTIC) Insider Trading and Institutional Ownership History

Insider Ownership Percentage: 2.72%
Institutional Ownership Percentage: 33.95%

Insider Trading History for CTI BioPharma (NASDAQ:CTIC)

Institutional Ownership by Quarter for CTI BioPharma (NASDAQ:CTIC)

CTI BioPharma (NASDAQ CTIC) Insider Trading History

Transaction Date	Insider Name	Title	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
2/9/2018	Bvf Partners L P/Il	Major Shareholder	Buy	5,634,108	$3.00	$16,902,324.00
2/9/2018	Value Fund L P Biotechnology	Insider	Buy	6,333,333	$3.00	$18,999,999.00
9/29/2017	Richard L Love	Director	Sell	14,600	$3.21	$46,866.00	84,318
6/24/2016	James A Bianco	CEO	Sell	10,000	$0.37	$3,700.00	1,780,133
5/27/2016	James A Bianco	CEO	Sell	10,000	$0.45	$4,500.00	1,790,133
4/29/2016	James A Bianco	CEO	Sell	10,000	$0.52	$5,200.00	1,800,133
3/28/2016	James A Bianco	CEO	Sell	10,000	$0.49	$4,900.00	1,810,133
3/21/2016	James A Bianco	CEO	Sell	318,169	$0.55	$174,992.95	1,820,133
3/4/2016	Matthew Plunkett	EVP	Sell	10,000	$0.59	$5,900.00	598,784
2/26/2016	Jack W Singer	EVP	Sell	15,000	$0.63	$9,450.00	1,054,892
2/26/2016	James A Bianco	CEO	Sell	10,000	$0.63	$6,300.00	2,138,302
2/16/2016	James A Bianco	CEO	Sell	100,000	$0.42	$42,000.00	2,148,302
2/4/2016	Matthew Plunkett	EVP	Sell	10,000	$1.15	$11,500.00	600,084
1/29/2016	Jack W. Singer	EVP	Sell	15,000	$1.18	$17,700.00	1,054,992
1/29/2016	James A Bianco	CEO	Sell	10,000	$1.20	$12,000.00	2,248,302
1/8/2016	Value Fund L P Biotechnology	Insider	Buy	1,001,327	$1.22	$1,221,618.94
1/4/2016	Matthew Plunkett	EVP	Sell	10,000	$1.21	$12,100.00	610,084
12/30/2015	James A. Bianco	CEO	Sell	110,000	$1.26	$138,600.00	2,258,302
12/28/2015	James A. Bianco	CEO	Sell	10,000	$1.29	$12,900.00	2,258,302
12/18/2015	Jack W. Singer	EVP	Sell	15,000	$1.18	$17,700.00	1,306,850
12/4/2015	Matthew Plunkett	EVP	Sell	10,000	$1.00	$10,000.00	620,084
11/27/2015	Jack W. Singer	EVP	Sell	15,000	$1.21	$18,150.00	1,321,850
11/27/2015	James A Bianco	CEO	Sell	10,000	$1.23	$12,300.00	2,951,519
11/19/2015	Louis A. Bianco	EVP	Sell	15,000	$1.13	$16,950.00	906,347
10/30/2015	James A Bianco	CEO	Sell	260,000	$1.35	$351,000.00	2,961,519
10/29/2015	Louis A. Bianco	EVP	Sell	10,000	$1.41	$14,100.00	921,347
10/23/2015	Jack W. Singer	EVP	Sell	15,000	$1.62	$24,300.00	1,336,850
10/22/2015	Louis A Bianco	EVP	Sell	10,000	$1.58	$15,800.00	931,347
10/5/2015	Matthew Plunkett	EVP	Sell	10,000	$1.52	$15,200.00	640,084
9/30/2015	Jack W. Singer	EVP	Sell	100,000	$1.42	$142,000.00	1,351,850
9/30/2015	James A. Bianco	CEO	Sell	600,000	$1.43	$858,000.00	3,221,519
9/30/2015	Richard L. Love	Director	Sell	13,660	$1.45	$19,807.00	530,449
9/29/2015	Louis A. Bianco	EVP	Sell	170,000	$1.41	$239,700.00	941,347
9/25/2015	Jack W. Singer	EVP	Sell	15,000	$1.64	$24,600.00	1,451,850
9/24/2015	Matthew Plunkett	EVP	Sell	75,869	$1.57	$119,114.33	725,084
9/4/2015	Matthew Plunkett	EVP	Sell	10,000	$1.54	$15,400.00	649,214
8/28/2015	Jack W. Singer	EVP	Sell	15,000	$1.58	$23,700.00	1,260,919
7/24/2015	Jack W Singer	EVP	Sell	15,000	$1.91	$28,650.00
7/23/2015	Louis A Bianco	EVP	Sell	10,000	$1.91	$19,100.00
7/6/2015	Matthew Plunkett	EVP	Sell	10,000	$1.95	$19,500.00
6/26/2015	Jack W Singer	EVP	Sell	15,000	$2.07	$31,050.00
6/25/2015	Louis A Bianco	EVP	Sell	10,000	$2.18	$21,800.00
6/4/2015	Matthew Plunkett	EVP	Sell	10,000	$2.06	$20,600.00
5/22/2015	Jack W Singer	EVP	Sell	15,000	$1.74	$26,100.00
5/21/2015	Louis A Bianco	EVP	Sell	10,000	$1.80	$18,000.00
5/4/2015	Matthew Plunkett	EVP	Sell	10,000	$1.86	$18,600.00
4/24/2015	Jack W Singer	EVP	Sell	15,000	$1.96	$29,400.00
4/23/2015	Louis A Bianco	EVP	Sell	10,000	$1.93	$19,300.00
4/6/2015	Matthew Plunkett	EVP	Sell	16,569	$1.88	$31,149.72
3/23/2015	James A Bianco	CEO	Sell	175,199	$1.95	$341,638.05
3/23/2015	Matthew Plunkett	EVP	Sell	59,130	$1.96	$115,894.80
3/20/2015	Louis A Bianco	EVP	Sell	63,000	$1.94	$122,220.00
2/27/2015	Jack W Singer	EVP	Sell	15,000	$2.35	$35,250.00
2/5/2015	Louis A Bianco	EVP	Sell	10,000	$2.22	$22,200.00
2/4/2015	Matthew Plunkett	EVP	Sell	12,000	$2.22	$26,640.00
1/8/2015	Louis A Bianco	EVP	Sell	10,000	$2.32	$23,200.00
1/5/2015	Matthew Plunkett	EVP	Sell	12,000	$2.36	$28,320.00
12/19/2014	James A Bianco	CEO	Sell	40,000	$2.44	$97,600.00
12/4/2014	Louis A Bianco	EVP	Sell	10,000	$2.25	$22,500.00
11/6/2014	Louis A Bianco	EVP	Sell	10,000	$2.37	$23,700.00
10/6/2014	Matthew Plunkett	EVP	Sell	12,000	$2.39	$28,680.00
9/23/2014	Matthew Plunkett	EVP	Sell	103,635	$2.56	$265,305.60
9/22/2014	James A Bianco	CEO	Sell	307,068	$2.53	$776,882.04
9/22/2014	Matthew Plunkett	EVP	Sell	51,817	$2.58	$133,687.86
9/19/2014	Louis A Bianco	EVP	Sell	145,000	$2.59	$375,550.00
9/4/2014	Matthew Plunkett	EVP	Sell	27,301	$2.48	$67,706.48
8/15/2014	James A Bianco	CEO	Sell	40,000	$2.54	$101,600.00
8/4/2014	Matthew Plunkett	EVP	Sell	12,000	$2.48	$29,760.00
7/10/2014	Louis A Bianco	EVP	Sell	10,000	$2.73	$27,300.00
7/7/2014	Matthew Plunkett	EVP	Sell	12,000	$2.89	$34,680.00
6/27/2014	James A Bianco	CEO	Sell	50,000	$2.84	$142,000.00
6/5/2014	Louis A Bianco	EVP	Sell	10,000	$2.97	$29,700.00
5/1/2014	Louis Bianco	EVP	Sell	10,000	$2.91	$29,100.00	812,897
3/28/2014	Vartan Gregorian	Director	Sell	82,000	$3.41	$279,620.00	468,937
3/25/2014	Phillip Phd Nudelman	Director	Sell	100,000	$3.56	$356,000.00	448,619
3/24/2014	Jack Singer	EVP	Sell	60,000	$3.47	$208,200.00	1,035,234
3/21/2014	James Bianco	CEO	Sell	395,000	$3.83	$1,512,850.00	2,402,794
3/21/2014	Matthew Plunkett	EVP	Sell	170,000	$3.73	$634,100.00	620,904
3/7/2014	Fred Telling	Director	Sell	72,095	$3.75	$270,356.25	401,170
9/23/2013	James A Bianco	CEO	Sell	130,551	$1.50	$195,826.50
8/30/2013	James A Bianco	CEO	Sell	25,925	$1.08	$27,999.00
8/9/2013	James A Bianco	CEO	Sell	40,000	$1.07	$42,800.00
8/7/2013	Mary Oneil Mundinger	Director	Sell	125,000	$1.06	$132,500.00
8/6/2013	Phillip M Phd Nudelman	Director	Sell	50,000	$1.09	$54,500.00
7/26/2013	James A Bianco	CEO	Sell	25,688	$1.09	$27,999.92
6/28/2013	James A Bianco	CEO	Sell	26,053	$1.08	$28,137.24
6/5/2013	Jack W Singer	EVP	Sell	10,000	$1.26	$12,600.00
5/31/2013	James A Bianco	CEO	Sell	28,000	$1.22	$34,160.00
5/31/2013	Louis A Bianco	EVP	Sell	33,712	$1.24	$41,802.88
5/30/2013	Fred Telling	Director	Sell	64,798	$1.24	$80,349.52
5/24/2013	Richard L Love	Director	Sell	23,000	$1.21	$27,830.00
5/10/2013	James A Bianco	CEO	Sell	25,000	$1.16	$29,000.00
5/9/2013	Louis A Bianco	EVP	Sell	50,000	$1.15	$57,500.00
3/11/2013	Jack W Singer	EVP	Sell	13,000	$1.28	$16,640.00
8/10/2012	James A Bianco	CEO	Sell	10,000	$0.42	$4,200.00

(Data available from 1/1/2013 forward)

CTI BioPharma (NASDAQ CTIC) News Headlines

Source:

Date	Headline
	CTI BioPharma (CTIC) Raised to Hold at Zacks Investment Research www.americanbankingnews.com - April 25 at 7:54 PM
	Does CTI BioPharma Corp’s (NASDAQ:CTIC) Latest Financial Perfomance Look Strong? finance.yahoo.com - April 25 at 4:39 PM
	$10.30 Million in Sales Expected for CTI BioPharma (CTIC) This Quarter www.americanbankingnews.com - April 24 at 3:02 AM
	Zacks: Analysts Expect CTI BioPharma (CTIC) Will Post Earnings of -$0.07 Per Share www.americanbankingnews.com - April 22 at 1:16 PM
	What Should You Know About CTI BioPharma Corp’s (NASDAQ:CTIC) Earnings Trajectory? finance.yahoo.com - April 18 at 4:46 PM
	CTI BioPharma (CTIC) Rating Lowered to Sell at Zacks Investment Research www.americanbankingnews.com - April 17 at 10:19 PM
	Analyzing CTI BioPharma (CTIC) & Amarin (AMRN) www.americanbankingnews.com - April 9 at 11:13 AM
	Needham & Company Starts CTI BioPharma (CTIC) at Buy www.streetinsider.com - April 7 at 9:57 AM
	$10.30 Million in Sales Expected for CTI BioPharma Corp (CTIC) This Quarter www.americanbankingnews.com - April 7 at 2:48 AM
	Analysts Anticipate CTI BioPharma Corp (CTIC) to Post -$0.07 EPS www.americanbankingnews.com - April 5 at 3:18 PM
	CTI BioPharma Corp (CTIC) Receives Consensus Rating of "Buy" from Brokerages www.americanbankingnews.com - April 1 at 9:37 AM
	Seeing Value In CTI BioPharma: Compelling Data, Recent M&A Validate Pacritinib In Myelofibrosis seekingalpha.com - March 29 at 4:29 PM
	CTI BioPharma pays CEO $5.6 million in his first year www.bizjournals.com - March 29 at 4:29 PM
	CTI BioPharma (CTIC) Earns Buy Rating from Analysts at Needham & Company LLC www.americanbankingnews.com - March 26 at 8:37 AM
	CTI BioPharma Corp (CTIC) Expected to Post Quarterly Sales of $10.30 Million www.americanbankingnews.com - March 21 at 8:49 AM
	SA Interview: Biotechnology Investing With Juggernaut Capital - CTI ... - Seeking Alpha seekingalpha.com - March 19 at 4:23 PM
	SA Interview: Biotechnology Investing With Juggernaut Capital - Seeking Alpha seekingalpha.com - March 19 at 4:23 PM
	Brokerages Expect CTI BioPharma Corp (CTIC) to Post -$0.07 EPS www.americanbankingnews.com - March 19 at 3:16 PM
	Active-Investors: Wired News - CTI BioPharma's Pacritinib Phase-3 PERSIST-2 Clinical Trial Data Published in JAMA Oncology www.finanznachrichten.de - March 13 at 9:45 AM
	CTI BioPharma Corp (CTIC) to Post Q1 2018 Earnings of ($0.07) Per Share, Jefferies Group Forecasts www.americanbankingnews.com - March 12 at 2:32 AM
	CTI BioPharma (CTIC) Earns Outperform Rating from Analysts at JMP Securities www.americanbankingnews.com - March 11 at 3:19 PM
	CTI BioPharma (CTIC) Reports Publication of Pacritinib Phase 3 PERSIST-2 Clinical Trial in JAMA www.streetinsider.com - March 9 at 5:31 PM
	CTI BioPharma Announces Publication of Pacritinib Phase 3 PERSIST-2 Clinical Trial in JAMA Oncology finance.yahoo.com - March 9 at 9:58 AM
	CTI BioPharma to Present at Upcoming Investor Conferences finance.yahoo.com - March 9 at 9:58 AM
	CTI BioPharma (CTIC) Rating Reiterated by Cann www.americanbankingnews.com - March 8 at 12:28 AM
	CTI BioPharma (CTIC) Releases Quarterly Earnings Results, Misses Expectations By $0.04 EPS www.americanbankingnews.com - March 7 at 9:14 PM
	CTI BioPharma Corp (NASDAQ:CTIC): What Does It Mean For Your Portfolio? finance.yahoo.com - March 7 at 5:17 PM
	CTI BioPharma Reports Fourth Quarter and Full Year 2017 Financial Results www.prnewswire.com - March 7 at 4:07 PM
	CTI BioPharma Corp (CTIC) Receives Consensus Recommendation of "Buy" from Analysts www.americanbankingnews.com - March 7 at 2:08 PM
	Stonepine Capital Management LLC Purchases 841,838 Shares of CTI BioPharma Corp (CTIC) www.americanbankingnews.com - March 6 at 10:02 AM
	$1.00 Million in Sales Expected for CTI BioPharma Corp (CTIC) This Quarter www.americanbankingnews.com - March 4 at 7:38 AM
	Zacks: Brokerages Expect CTI BioPharma Corp (CTIC) to Announce -$0.29 Earnings Per Share www.americanbankingnews.com - March 2 at 7:12 PM
	When Will CTI BioPharma Corp (NASDAQ:CTIC) Breakeven? finance.yahoo.com - February 28 at 5:01 PM
	CTI BioPharma to Report Fourth Quarter and Full Year 2017 Financial Results on March 7, 2018 finance.yahoo.com - February 28 at 9:22 AM
	CTI BioPharma (CTIC) Now Covered by Analysts at Oppenheimer www.americanbankingnews.com - February 23 at 9:10 PM
	CTI BioPharma (CTIC) Now Covered by Cann www.americanbankingnews.com - February 23 at 12:44 PM
	CTI BioPharma (CTIC) to Release Quarterly Earnings on Wednesday www.americanbankingnews.com - February 21 at 2:22 AM
	CTI BioPharma (CTIC) Presents At Leerink Partners 7th Annual Global Healthcare Conference - Slideshow seekingalpha.com - February 16 at 4:37 PM
	Jefferies Group Analysts Increase Earnings Estimates for CTI BioPharma Corp (CTIC) www.americanbankingnews.com - February 15 at 11:40 AM
	CTI BioPharma to Present at the 7th Annual Leerink Partners Global Healthcare Conference finance.yahoo.com - February 14 at 4:49 PM
	CTI BioPharma Announces Closing Of Underwritten Public Offering Of Common Stock finance.yahoo.com - February 13 at 9:10 AM
	CTI BioPharma Corp (CTIC) Major Shareholder Bvf Partners L. P/Il Acquires 5,634,108 Shares www.americanbankingnews.com - February 13 at 12:28 AM
	Insider Buying: CTI BioPharma Corp (CTIC) Insider Purchases 6,333,333 Shares of Stock www.americanbankingnews.com - February 13 at 12:28 AM
	Bio-Path (BPTH) versus CTI BioPharma (CTIC) Financial Comparison www.americanbankingnews.com - February 10 at 5:02 PM
	CTI BioPharma Prices Underwritten Public Offering of $60 Million of Common Stock www.prnewswire.com - February 9 at 7:31 AM
	CTI BioPharma (CTIC) Launches Follow-On Offering of Common Stock - StreetInsider.com www.streetinsider.com - February 6 at 9:09 AM
	BrainStorm Cell Therapeutics to Present at the BIO CEO & Investor Conference www.prnewswire.com - February 6 at 5:55 AM
	CTI BioPharma (CTIC) Launches Follow-On Offering of Common Stock www.streetinsider.com - February 5 at 4:22 PM
	CTI BioPharma Announces Launch of Follow-On Offering finance.yahoo.com - February 5 at 9:09 AM
	Who Owns CTI BioPharma Corp (NASDAQ:CTIC)? finance.yahoo.com - January 30 at 9:35 AM

CTI BioPharma (NASDAQ:CTIC) SEC Filings

Form Type:

Ownership Filings:

This page is loading this company's SEC Filings. Please wait...

CTI BioPharma (NASDAQ:CTIC) Income Statement, Balance Sheet and Cash Flow Statement

CTI BioPharma (NASDAQ CTIC) Stock Chart for Wednesday, April, 25, 2018

Loading chart…

This page was last updated on 4/25/2018 by MarketBeat.com Staff